Skip to main content

LON:VENN - Venn Life Sciences Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 6.85
▲ +0.45 (7.03%)
1 month | 3 months | 12 months
Get New Venn Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VENN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VENN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Venn Life Sciences in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 6.85.

N/A

The current consensus among 0 investment analysts is to n/a stock in Venn Life Sciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/5/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
9/29/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
8/4/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
5/11/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
i
(Data available from 5/8/2016 forward)
Venn Life Sciences logo
Venn Life Sciences Holdings Plc, a clinical research organization, provides consulting and clinical trial services to pharmaceutical, biotechnology, and medical device companies in the United Kingdom, Ireland, France, the Netherlands, Germany, and Singapore. The company offers drug development planning and strategy services, including clinical feasibility assessment, project management, and in-licensing and technical due diligence; and early drug development services, such as drug candidate selection, CMC, non-clinical/pre-clinical development, clinical pharmacology, pharmacokinetics, and pharmacometrics and PK-PD modelling. It also provides clinical trial services comprising clinical feasibility assessment, project management, clinical and medical monitoring, biometrics, biostatistics, data management and databases integration, ISC/IDMC, RTSM, investigator initiated studies, and resourcing and recruitment. In addition, the company offers regulatory affairs and consulting, quality assurance, and legal services, as well as drug development training and courses. The company has a strategic collaboration with Open Orphan DAC for the clinical research and regulatory consulting for companies developing products under the auspices of the various Orphan Drug frameworks. The company was founded in 2012 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: GBX 6.85
6.70
7

50 Day Range

MA: GBX 6.85
6.85
6.85

52 Week Range

Now: GBX 6.85
1.55
7.25

Volume

1,027,544 shs

Average Volume

566,253 shs

Market Capitalization

£4.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Venn Life Sciences?

The following sell-side analysts have issued reports on Venn Life Sciences in the last twelve months:
View the latest analyst ratings for VENN.

What is the current price target for Venn Life Sciences?

0 Wall Street analysts have set twelve-month price targets for Venn Life Sciences in the last year. has the lowest price target set, forecasting a price of £100,000 for Venn Life Sciences in the next year.
View the latest price targets for VENN.

What is the current consensus analyst rating for Venn Life Sciences?

Venn Life Sciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VENN.

What other companies compete with Venn Life Sciences?

How do I contact Venn Life Sciences' investor relations team?

Venn Life Sciences' physical mailing address is 1 Berkeley Street, LONDON, W1J 8DJ, United Kingdom. The company's listed phone number is +44-28-90737900. The official website for Venn Life Sciences is www.vennlifesciences.com.